000111655 001__ 111655 000111655 005__ 20230519145527.0 000111655 0247_ $$2doi$$a10.37201/req/019.2021 000111655 0248_ $$2sideral$$a127393 000111655 037__ $$aART-2021-127393 000111655 041__ $$aeng 000111655 100__ $$aCanton, R. 000111655 245__ $$aAntimicrobial activity of ceftolozane-tazobactam against Enterobacterales and Pseudomonas aeruginosa recovered during the Study for Monitoring Antimicrobial Resistance Trends (SMART) program in Spain (2016-2018) 000111655 260__ $$c2021 000111655 5060_ $$aAccess copy available to the general public$$fUnrestricted 000111655 5203_ $$aObjective. To analyse the susceptibility to ceftolozane-tazobactam and comparators in Enterobacterales and Pseudomonas aeruginosa isolates recovered from intraabdominal (IAI), urinary (UTI), respiratory (RTI) and bloodstream infection (BSI) in the SMART (Study for Monitoring Antimicrobial Resistance Trends) study. Methods. The susceptibility of 5, 351 isolates collected in 11 Spanish hospitals (2016-2018) were analysed (EUCAST-2020 criteria) by broth microdilution and were phenotypically studied for the presence of extended-spectrum beta-lactamases (ESBL). Ceftolozane-tazobactam and/or carbapenem resistant isolates were genetically characterized for ESBL and carbapenemases. Results. Escherichia coli was the most frequent pathogen (49.3% IAI, 54.9% UTI, 16.7% RTI and 50% BSI), followed by Klebsiella pneumoniae (11.9%, 19.1%, 13.1% and 15.4%, respectively). P. aeruginosa was isolated in 9.3%, 5.6%, 32% and 9%, respectively. The frequency of isolates with ESBLs (2016-2017) was: 30.5% K. pneumoniae, 8.6% E. coli, 2.3% Klebsiella oxytoca and 0.7% Proteus mirabilis. Ceftolozane-tazobactam was very active against non-ESBL-(99.3% susceptible) and ESBL-(95.2%) producing E. coli being less active against K. pneumoniae (98% and 43.1%, respectively) isolates. CTX-M-15 was the most prevalent ESBL in E. coli (27.5%) and K. pneumoniae (51.9%) frequently associated with OXA-48-like carbapenemase. Overall, 93% of P. aeruginosa isolates were susceptible to ceftolozane-tazobactam, preserving this activity (>75%) in isolates resistant to other beta-lactams except in those resistant to meropenen or ceftazidime-avibactam. GES-5, PER-1, VIM-1/2 were the most prevalent enzymes in isolates resistant to ceftolozane-tazobactam. Conclusions. Ceftolozane-tazobactam showed high activity rates against isolates recovered in the SMART study although it was affected in K. pneumoniae and P. aeruginosa isolates with ESBL and/or carbapenemases. 000111655 540__ $$9info:eu-repo/semantics/openAccess$$aby-nc$$uhttp://creativecommons.org/licenses/by-nc/3.0/es/ 000111655 590__ $$a2.515$$b2021 000111655 592__ $$a0.44$$b2021 000111655 594__ $$a2.3$$b2021 000111655 591__ $$aPHARMACOLOGY & PHARMACY$$b206 / 279 = 0.738$$c2021$$dQ3$$eT3 000111655 593__ $$aMicrobiology (medical)$$c2021$$dQ3 000111655 591__ $$aMICROBIOLOGY$$b116 / 138 = 0.841$$c2021$$dQ4$$eT3 000111655 593__ $$aMedicine (miscellaneous)$$c2021$$dQ3 000111655 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion 000111655 700__ $$aLoza, E. 000111655 700__ $$aArcay, R.M. 000111655 700__ $$aCercenado, E. 000111655 700__ $$0(orcid)0000-0002-2519-701X$$aCastillo, F.J.$$uUniversidad de Zaragoza 000111655 700__ $$aCisterna, R. 000111655 700__ $$aGalvez-Benitez, L. 000111655 700__ $$aGonzález Romo, F. 000111655 700__ $$aHernandez-Cabezas, A. 000111655 700__ $$aRodriguez-Lozano, J. 000111655 700__ $$aSuarez-Barrenechea, A.I. 000111655 700__ $$aTubau, F. 000111655 700__ $$aDiaz-Reganon, J. 000111655 700__ $$aLopez-Mendoza, D. 000111655 7102_ $$11011$$2630$$aUniversidad de Zaragoza$$bDpto. Microb.Ped.Radio.Sal.Pú.$$cÁrea Microbiología 000111655 773__ $$g34, 3 (2021), 228-237$$pRev. esp. quimioter.$$tRevista española de quimioterapia$$x0214-3429 000111655 8564_ $$s505343$$uhttps://zaguan.unizar.es/record/111655/files/texto_completo.pdf$$yVersión publicada 000111655 8564_ $$s2906778$$uhttps://zaguan.unizar.es/record/111655/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada 000111655 909CO $$ooai:zaguan.unizar.es:111655$$particulos$$pdriver 000111655 951__ $$a2023-05-18-15:27:25 000111655 980__ $$aARTICLE